Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | CPA1 | P15085 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139496 | 0.90 | HPGD (0.48) | MEN1KMT2ALMNASMN1; SMN2CTSB | |
| SCHEMBL7131848 | 0.88 | MEN1 (0.50) | MEN1KMT2ALMNASMN1; SMN2CTSB | |
| SCHEMBL7136919 | 0.87 | MEN1 (0.44) | MEN1KMT2ALMNACTSBCTSL | |
| SCHEMBL7138103 | 0.87 | CTSS (0.51) | MEN1KMT2ALMNACTSBCTSL | |
| SCHEMBL7796796 | 0.85 | ACE (0.43) | SMN1; SMN2CTSBCTSLCTSSMMP12 | |
| SCHEMBL7132066 | 0.85 | HPGD (0.41) | MEN1KMT2ALMNASMN1; SMN2CTSB | |
| SCHEMBL7139609 | 0.85 | ELANE (0.43) | MEN1KMT2ALMNACTSBCTSL | |
| SCHEMBL7133743 | 0.84 | ELANE (0.46) | MEN1KMT2ASMN1; SMN2ACEMME | |
| SCHEMBL7136450 | 0.83 | LMNA (0.55) | MEN1KMT2ALMNASMN1; SMN2CTSB | |
| SCHEMBL7139696 | 0.83 | LNPEP (0.43) | SMN1; SMN2CTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | MEN1 4105/4885KMT2A 4353/4885LMNA 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.